BioSpace News Archive

Milestone Phase II Clinical Study Demonstrates Niagen ® , Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD).

Silence Therapeutics plc today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of a second undisclosed milestone related to the first target under the collaboration.

QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

Anixa Biosciences, Inc. today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to SLS009, a highly selective CDK9 inhibitor, for the treatment of pediatric acute lymphoblastic leukemia (ALL).

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference at 7:00 am ET on June 27, 2024.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

Cypris Therapeutics, a drug discovery company, has launched following a breakthrough in synthetic chemistry technology which allows development of novel chemistries for treatment of therapeutically resistant diseases, including brain and pancreatic cancers.

Arvinas, Inc. announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D.

Radical Imaging, a trailblazer in medical imaging viewer solutions, proudly announces that FlexView Diagnostic, its SaaS web DICOM viewer product, received FDA clearance for diagnostic use.